No Data
No Data
Express News | Janux Therapeutics Inc : Leerink Partners Cuts Target Price to $89 From $91
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $36 to $100
Janux Therapeutics Price Target Lowered to $36 From $41 at Scotiabank
Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (TBPH), Immunocore Holdings (IMCR) and Janux Therapeutics Inc (JANX)
Buy Rating Affirmed for Janux Therapeutics: Promising Clinical Data and Superior Efficacy of Lead Program JANX007
Janux Therapeutics Inc: Undervalued Growth Potential Amid Recent Stock Pullback